skip to Global Navigation Bar skip to main content


homeHome > Global Business > Introduction

Introduction

Daewoong provides the most beneficial total solution,
To contribute in improving quality of life

COMPANY OVERVIEW

Daewoong Group is a global healthcare group established in 1945 under the vision to ‘manufacture high quality pharmaceuticals to enhance people’s health and create a healthy society’.

As it is our vision to be a global healthcare group, Daewoong has established 3 manufacturing sites in Indonesia and China and 8 branch offices in China, Japan, Indonesia, Thailand, Vietnam, Philippines, India and USA. Through our global presence, we are actively striving to export our high value added portfolio to the world.

A global healthcare group dedicated to improving quality of life To provide the most beneficial total solutions in pharmaceuticals and services that contribute to improving quality of life of valued consumers justice Fairness Ownership Open mind Win-win-win

To achieve our mission to provide the most beneficial total solutions in pharmaceuticals and services that contribute to improving the quality of life of valued consumers, we have been reinforcing R&D capacities through the establishment of R&D centers globally in Korea, China, India and Indonesia and focusing on developing new chemical entities, biologics, incrementally modified drugs and high-value added APIs.

HISTORY

1945
Established as Daehan
Chemical Industry Co. Ltd
1961
Launched URSA (Ursodeoxycholic Acid)
1978
Changed Corporate Name to
Daewoong Pharmaceutical Co.Ltd
1983
Established Daewoong Chemical Co.Ltd
(Now Daewoong Bio. Inc)
1992
Established HyangnamManufacturing Plant
2001
Launched Easyef,
the 1st Bioengineered Product in Korea
2008
Established ChinaBranch Office
2009
Established India Research Center
Daewoong America Corporation,
and Beijing Research Center
2011
Completion of Daewoong Bio API
Manufacturing plant
2013
- Acquired Liaoning Baifeng,
Chinese drug manufacturer
- Expanded Hyangnam Plant (cGMP grade)
2014
Established Daewoong Liaoning R&D Institute
in China
2015
- Established 1st Biopharmaceutical
Manufacturing plant in Indonesia
- Acquired HANALL BIOPHARMA Co. Ltd
2016
- Completion of Daewoong Lifescience Lab
‘Bio-innovation Center’
- Completion of Osong cGMP
Manufacturing Plant
- Received National Award for Quality
Management
2017
- Established overseas corporation in Japan
- Biosimilar ‘Epodion’ approved by
Indonesia BPOM
- Became shareholder of Trapharco of Vietnam